Wang K, Semple MG, Moore M, et al. - In this pragmatic trial, researchers ascertained if early co-amoxiclav use decreases re-consultation due to clinical deterioration in “at risk” children presenting with influenza-like illness (ILI) in primary or ambulatory care.“At risk” children aged 6 months to 12 years presenting within f5 days of ILI onset have been randomly assigned to oral co-amoxiclav 400/57 or placebo twice daily for 5 days (dosing based on age ± weight). Between February 11, 2015, and April 20, 2018, 271 children were recruited. The trial found no evidence that co-amoxiclav treatment reduces the risk of re-consultation due to clinical deterioration in “at risk” children who present early with ILI during influenza season. As a result, the findings do not support the use of co-amoxiclav early in children with seasonal ILI.